HCA Healthcare (NYSE:HCA) Investment Analysis

Ben Hendrix from RBC Capital sets a price target of $401 for HCA Healthcare, indicating a potential increase of approximately 19.96%. HCA's financial health is robust, with strong revenue and EPS growth, share repurchases, and manageable debt levels. The stock's current performance and valuation suggest HCA Healthcare is a strong buy, with a potential total return of 25% from current levels.

HCA Healthcare (NYSE:HCA) is a leading hospital chain in the United States, known for its exceptional management and robust financial performance. The company provides essential healthcare services and has a strong presence in the sector. HCA's financial health and strategic initiatives make it an attractive option for investors looking to diversify their portfolios.

On July 28, 2025, Ben Hendrix from RBC Capital set a price target of $401 for HCA. At that time, HCA's stock was priced at $334.29, suggesting a potential increase of approximately 19.96%. As of now, the stock price has risen to $337.33, reflecting a $3.01 increase or about 0.90%. This upward trend indicates positive market sentiment towards HCA.

HCA's recent financial results show strong revenue and earnings per share (EPS) growth. The company is actively repurchasing shares and maintaining manageable debt levels, which supports strong shareholder returns. With a 16x multiple on 2025 EPS, HCA's fair value is estimated at $416 per share, implying a potential total return of 25% from current levels.

The stock has traded between $331.70 and $338.17 today, with a market capitalization of approximately $81.15 billion. Over the past year, HCA's stock has reached a high of $417.14 and a low of $289.98. The current valuation and financial performance highlight HCA Healthcare as a strong buy, as noted by Ben Hendrix's price target and the company's ongoing strategic efforts.